Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-747-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$179.80 million
Profitability
Miscellaneous
Employees483
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($3.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.57) by $0.46. The biopharmaceutical company earned $52.25 million during the quarter, compared to analysts' expectations of $52.15 million. Intercept Pharmaceuticals had a negative return on equity of 617.23% and a negative net margin of 162.49%. The company's quarterly revenue was up 45.3% on a year-over-year basis. During the same quarter last year, the business posted ($3.22) EPS. View Intercept Pharmaceuticals' Earnings History.
When is Intercept Pharmaceuticals' next earnings date?
What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?
Intercept Pharmaceuticals updated its FY 2019 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $235-245 million, compared to the consensus revenue estimate of $236.91 million.
What price target have analysts set for ICPT?
21 equities research analysts have issued 12-month price targets for Intercept Pharmaceuticals' shares. Their predictions range from $68.00 to $243.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $148.1010 in the next year. This suggests a possible upside of 68.2% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.
What is the consensus analysts' recommendation for Intercept Pharmaceuticals?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $170 PT. Positive Ph3 data on fibrosis de-risk this binary readout. Intercept announced this morning that the 25mg dose hit on one of the key endpoints, which is a one point change in fibrosis stage (OCA 23.1%, placebo 11.9%, p-value=0.0002). They saw a numerical trend on NASH resolution in the 25mg. Although this endpoint did not hit (25mg p-value=0.1268), we believe that the data profile for OCA will support approval; fibrosis is relevant for potential liver outcomes. Since there was a p-value of 0.0013 when F1 co-morbidities were added, we are interested to see more analysis around NASH resolution." (2/19/2019)
- 2. According to Zacks Investment Research, "Intercept got a significant boost with the approval of Ocaliva for the treatment of PBC. Although sales had earlier taken a hit due to the safety issues regarding Ocaliva, management’s efforts to increase awareness about the updated level and promote Ocaliva, thereafter, is reaping results. While we are pleased with the approval of Ocaliva, the company’s dependence on a single product for growth has its risks. Any negative news related to Ocaliva would adversely impact Intercept and its growth prospects. The lack of other candidates in the pipeline is concerning. Nevertheless, the company is looking to expand the drug’s label in the promising NASH and PSC space. The phase III NASH program includes the REGENERATE trial among patients with advanced liver fibrosis and the REVERSE trial among patients with compensated cirrhosis. Shares have outperformed the industry in the last six months." (2/15/2019)
Has Intercept Pharmaceuticals been receiving favorable news coverage?
Media stories about ICPT stock have been trending negative recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intercept Pharmaceuticals earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA), Catalent (CTLT), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY) and GALAPAGOS NV/S (GLPG).
What other stocks do shareholders of Intercept Pharmaceuticals own?
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
- Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
- Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
- Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
- Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Trust Advisors LP (3.03%), Altrinsic Global Advisors LLC (0.94%), Geode Capital Management LLC (0.93%), Northern Trust Corp (0.91%), Samsara BioCapital LLC (0.71%) and Jennison Associates LLC (0.62%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Rachel Mcminn, Richard J Kim, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.
Which major investors are selling Intercept Pharmaceuticals stock?
ICPT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Samsara BioCapital LLC, DekaBank Deutsche Girozentrale, Pinnacle Associates Ltd., Virtu Financial LLC, QVT Financial LP, Xact Kapitalforvaltning AB and State Board of Administration of Florida Retirement System. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David Shapiro, Lisa Bright, Mark Pruzanski, Paolo Fundaro, SPA Genextra and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.
Which major investors are buying Intercept Pharmaceuticals stock?
ICPT stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Emerald Advisers LLC, Federated Investors Inc. PA, Emerald Mutual Fund Advisers Trust, Spark Investment Management LLC, Candriam Luxembourg S.C.A., Frontier Capital Management Co. LLC and Marshall Wace North America L.P.. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener, Luca Benatti and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $88.03.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $2.62 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.
What is Intercept Pharmaceuticals' official website?
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
